within Pharmacolibrary.Drugs.N_NervousSystem.N01A_AnestheticsGeneral.N01AX03_Ketamine;

model Ketamine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.035833333333333e-05,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.00218,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0061600000000000005,
    k12 = 1.7333333333333336e-05,
    k21 = 1.7333333333333336e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ketamine</td></tr><tr><td>ATC code:</td><td>N01AX03</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.18</td><td>L</td></tr>
    <tr><td>clearance:</td><td>17.45</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ketamine is a dissociative anesthetic primarily used for anesthesia and analgesia. It acts as an NMDA receptor antagonist and is notable for its use in both human and veterinary medicine. Ketamine has also been researched and used off-label for treatment-resistant depression and acute pain management. It is approved and in clinical use as an anesthetic agent.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters of ketamine in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Hornik, CP, et al., &amp; Lee, JH (2018). Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children. <i>Journal of clinical pharmacology</i> 58(8) 1092–1104. DOI:<a href=\"https://doi.org/10.1002/jcph.1116\">10.1002/jcph.1116</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29677389/\">https://pubmed.ncbi.nlm.nih.gov/29677389</a></p></li><li><p>Fanta, S, et al., &amp; Kalso, E (2015). Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing. <i>European journal of clinical pharmacology</i> 71(4) 441–447. DOI:<a href=\"https://doi.org/10.1007/s00228-015-1826-y\">10.1007/s00228-015-1826-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25724645/\">https://pubmed.ncbi.nlm.nih.gov/25724645</a></p></li><li><p>Simons, P, et al., &amp; Dahan, A (2022). . <i>Frontiers in pain research (Lausanne, Switzerland)</i> 3 946486–None. DOI:<a href=\"https://doi.org/10.3389/fpain.2022.946486\">10.3389/fpain.2022.946486</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35899184/\">https://pubmed.ncbi.nlm.nih.gov/35899184</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N01AX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ketamine;
